  John Stageman, PhD, current vice president of AstraZeneca’s  biopharmaceutical strategic planning, will assume the role of interim site head  for the new MedImmune site in Cambridge, UK, after the name change from  Cambridge Antibody Technology (CAT), announced on October 29, 2007. 

  AstraZeneca acquired CAT in June 2006 with the intent to have  biologics account for 25 percent of its product pipeline by 2010. In 2007,  AstraZeneca accelerated achievement of this strategy with the acquisition of  MedImmune.

News

John Stageman, PhD, current vice president of AstraZeneca’s biopharmaceutical strategic planning, will assume the role of interim site head for the new MedImmune site in Cambridge, UK, after the name change from Cambridge Antibody Technology (CAT), announced on October 29, 2007.